Agilent Technologies stock (US00846U1016): Q1 earnings miss and upcoming Q2 report

Agilent Technologies reported Q1 2026 earnings on February 25, 2026, with EPS of $1.36 missing estimates by $0.01 and revenue of $1.80 billion slightly below expectations. Q2 results are due May 27.

Agilent Technologies, Inc. released its fiscal Q1 2026 earnings on February 25, 2026, reporting earnings per share of $1.36, which fell short of the consensus estimate of $1.37 by $0.01, according to MarketBeat as of 05/08/2026. Quarterly revenue increased 7.0% year-over-year to $1.80 billion, missing the $1.81 billion forecast. The stock closed at $115.52 on May 8, 2026, on the NYSE.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Agilent Technologies, Inc.
• Sector/industry: Scientific instrumentation and life sciences
• Headquarters/country: Santa Clara, California, USA
• Core markets: Life sciences, diagnostics, applied chemical markets
• Key revenue drivers: Instrumentation, consumables, software, services
• Home exchange/listing venue: NYSE (A)
• Trading currency: USD

Agilent Technologies Inc.: core business model

Agilent Technologies Inc. provides scientific instrumentation, consumables, software, and services for laboratories in life sciences, diagnostics, and applied chemical markets worldwide, according to its company profile on MarketBeat. The firm operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. This diversified model supports recurring revenue from consumables and services alongside instrument sales.

Headquartered in Santa Clara, California, Agilent serves pharmaceutical, biotechnology, academic, and government customers. Its products enable drug discovery, development, diagnostics, and environmental testing, making it a key player for US investors tracking biotech and healthcare innovation.

Main revenue and product drivers for Agilent Technologies Inc.

Agilent's trailing twelve-month revenue stood at $6.95 billion with net income of $1.30 billion as of the latest reports, per MarketBeat earnings data published May 2026. Key drivers include liquid chromatography systems, mass spectrometers, and genomics solutions. The Life Sciences segment, a major contributor, benefits from demand in biopharma R&D.

Consumables and services generate stable income, often comprising over 50% of revenue in peer firms. Agilent's CrossLab segment supports this with maintenance and optimization services, appealing to US institutional investors seeking defensive growth in medtech.

Industry trends and competitive position

The scientific instruments sector grows with advances in precision medicine and genomics, where Agilent holds strong positioning via innovations in mass spectrometry and cell analysis. US market exposure is significant, with biopharma spending driving demand amid a $100+ billion annual US R&D ecosystem.

Why Agilent Technologies Inc. matters for US investors

Listed on the NYSE, Agilent offers US investors direct access to life sciences tools critical for domestic biotech hubs like Boston and San Francisco. Its $32.65 billion market cap and beta of 1.22 reflect stability with moderate volatility, per MarketBeat data as of May 2026.

Conclusion

Agilent Technologies Inc. navigates a competitive landscape with solid fundamentals, as shown by its Q1 2026 results and analyst consensus. Upcoming Q2 earnings on May 27, 2026, could provide further clarity on growth trajectories in life sciences. The stock's position in high-demand sectors underscores its relevance amid US biotech expansion.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.